Botulinum toxin Type A is the world's most widely administered aesthetic injectable. In the UK and Europe, millions of treatments are performed each year — yet the clinical depth of many practitioners' understanding of the product they are injecting rarely matches the frequency with which they use it. Mechanism of action, unit non-equivalence between brands, dosing principles, anatomical targeting, and complication management are all areas where gaps in knowledge translate directly into suboptimal patient outcomes.

 

Botulism is a rare but serious disease that occurs when a bacterium called Clostridium botulinum produces a toxin. The toxin attacks the body’s nerves. It can happen as a result...